{"transactions":[{"id":951491,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-05T21:22:18.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026."}],"balance_after":240000,"derivative":{"exercise_price":11.49,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001951238-26-000003","document":"form4-01052026_090113.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195123826000003/form4-01052026_090113.xml","form_type":"4"}},{"id":998887,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-14T23:42:54.000Z","date":"2025-11-12","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":89047,"derivative":{"exercise_price":0.84,"expiration_date":"2029-07-04","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001951238-25-000005","document":"form4-11142025_111150.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195123825000005/form4-11142025_111150.xml","form_type":"4"}},{"id":998886,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-11-14T23:42:54.000Z","date":"2025-11-12","kind":"sale","planned":false,"acquired":false,"shares":136380,"price":8.8634,"value":1208790.492,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $8.8634, and the range of prices was between $8.62 and $9.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001951238-25-000005","document":"form4-11142025_111150.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195123825000005/form4-11142025_111150.xml","form_type":"4"}},{"id":998885,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-11-14T23:42:54.000Z","date":"2025-11-12","kind":"sale","planned":false,"acquired":false,"shares":30000,"price":8.9119,"value":267357.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $8.9119, and the range of prices was between $8.87 and $8.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":136380,"source":{"system":"sec-edgar","filing":"0001951238-25-000005","document":"form4-11142025_111150.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195123825000005/form4-11142025_111150.xml","form_type":"4"}},{"id":998884,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-11-14T23:42:54.000Z","date":"2025-11-12","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":0.84,"value":25200.0,"ownership":{"direct":true},"balance_after":166380,"source":{"system":"sec-edgar","filing":"0001951238-25-000005","document":"form4-11142025_111150.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195123825000005/form4-11142025_111150.xml","form_type":"4"}},{"id":1314774,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-01-03T21:30:36.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":274100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025."}],"balance_after":274100,"derivative":{"exercise_price":10.71,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":274100},"source":{"system":"sec-edgar","filing":"0001415889-25-000461","document":"form4-01032025_040126.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925000461/form4-01032025_040126.xml","form_type":"4"}},{"id":1332335,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-14T00:53:20.000Z","date":"2024-12-13","kind":"exercise","planned":false,"acquired":false,"shares":27272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":55461,"derivative":{"exercise_price":1.44,"expiration_date":"2031-12-13","underlying":"Common Stock","underlying_shares":27272},"source":{"system":"sec-edgar","filing":"0001415889-24-029377","document":"form4-12142024_121217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029377/form4-12142024_121217.xml","form_type":"4"}},{"id":1332334,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-14T00:53:20.000Z","date":"2024-12-12","kind":"exercise","planned":false,"acquired":false,"shares":117333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":119047,"derivative":{"exercise_price":0.84,"expiration_date":"2029-07-04","underlying":"Common Stock","underlying_shares":117333},"source":{"system":"sec-edgar","filing":"0001415889-24-029377","document":"form4-12142024_121217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029377/form4-12142024_121217.xml","form_type":"4"}},{"id":1332333,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-14T00:53:20.000Z","date":"2024-12-13","kind":"sale","planned":false,"acquired":false,"shares":27272,"price":12.0625,"value":328968.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $12.0625, and the range of prices were between $11.83 and $12.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":136380,"source":{"system":"sec-edgar","filing":"0001415889-24-029377","document":"form4-12142024_121217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029377/form4-12142024_121217.xml","form_type":"4"}},{"id":1332332,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-14T00:53:20.000Z","date":"2024-12-13","kind":"exercise","planned":false,"acquired":true,"shares":27272,"price":1.44,"value":39271.68,"ownership":{"direct":true},"balance_after":163652,"source":{"system":"sec-edgar","filing":"0001415889-24-029377","document":"form4-12142024_121217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029377/form4-12142024_121217.xml","form_type":"4"}},{"id":1332331,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-14T00:53:20.000Z","date":"2024-12-12","kind":"sale","planned":false,"acquired":false,"shares":117333,"price":12.2653,"value":1439124.4449,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $12.2653, and the range of prices were between $11.83 and $12.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":136380,"source":{"system":"sec-edgar","filing":"0001415889-24-029377","document":"form4-12142024_121217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029377/form4-12142024_121217.xml","form_type":"4"}},{"id":1332330,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-14T00:53:20.000Z","date":"2024-12-12","kind":"exercise","planned":false,"acquired":true,"shares":117333,"price":0.84,"value":98559.72,"ownership":{"direct":true},"balance_after":253713,"source":{"system":"sec-edgar","filing":"0001415889-24-029377","document":"form4-12142024_121217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029377/form4-12142024_121217.xml","form_type":"4"}},{"id":1333874,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-12T22:41:24.000Z","date":"2024-12-10","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.84,"expiration_date":"2029-07-04","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-24-029162","document":"form4-12122024_101220.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029162/form4-12122024_101220.xml","form_type":"4"}},{"id":1333873,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-12T22:41:24.000Z","date":"2024-12-10","kind":"sale","planned":false,"acquired":false,"shares":50000,"price":13.1525,"value":657625.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $13.1525, and the range of prices were between $12.95 and $13.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":136380,"source":{"system":"sec-edgar","filing":"0001415889-24-029162","document":"form4-12122024_101220.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029162/form4-12122024_101220.xml","form_type":"4"}},{"id":1333872,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-12T22:41:24.000Z","date":"2024-12-10","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":0.84,"value":42000.0,"ownership":{"direct":true},"balance_after":186380,"source":{"system":"sec-edgar","filing":"0001415889-24-029162","document":"form4-12122024_101220.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029162/form4-12122024_101220.xml","form_type":"4"}},{"id":1340489,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-07T00:15:51.000Z","date":"2024-12-06","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":50000,"derivative":{"exercise_price":0.84,"expiration_date":"2029-07-04","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-24-028567","document":"form4-12072024_121247.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028567/form4-12072024_121247.xml","form_type":"4"}},{"id":1340488,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-07T00:15:51.000Z","date":"2024-12-05","kind":"exercise","planned":false,"acquired":false,"shares":49640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":100000,"derivative":{"exercise_price":0.84,"expiration_date":"2029-07-04","underlying":"Common Stock","underlying_shares":49640},"source":{"system":"sec-edgar","filing":"0001415889-24-028567","document":"form4-12072024_121247.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028567/form4-12072024_121247.xml","form_type":"4"}},{"id":1340487,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-07T00:15:51.000Z","date":"2024-12-04","kind":"exercise","planned":false,"acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":149640,"derivative":{"exercise_price":0.84,"expiration_date":"2029-07-04","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001415889-24-028567","document":"form4-12072024_121247.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028567/form4-12072024_121247.xml","form_type":"4"}},{"id":1340486,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-07T00:15:51.000Z","date":"2024-12-06","kind":"sale","planned":false,"acquired":false,"shares":50000,"price":14.2323,"value":711615.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $14.2323, and the range of prices were between $14.00 and $14.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":136380,"source":{"system":"sec-edgar","filing":"0001415889-24-028567","document":"form4-12072024_121247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028567/form4-12072024_121247.xml","form_type":"4"}},{"id":1340485,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-07T00:15:51.000Z","date":"2024-12-06","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":0.84,"value":42000.0,"ownership":{"direct":true},"balance_after":186380,"source":{"system":"sec-edgar","filing":"0001415889-24-028567","document":"form4-12072024_121247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028567/form4-12072024_121247.xml","form_type":"4"}},{"id":1340484,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-07T00:15:51.000Z","date":"2024-12-05","kind":"sale","planned":false,"acquired":false,"shares":49640,"price":14.1346,"value":701641.544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $14.1346, and the range of prices were between $13.95 and $14.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":136380,"source":{"system":"sec-edgar","filing":"0001415889-24-028567","document":"form4-12072024_121247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028567/form4-12072024_121247.xml","form_type":"4"}},{"id":1340483,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-07T00:15:51.000Z","date":"2024-12-05","kind":"exercise","planned":false,"acquired":true,"shares":49640,"price":0.84,"value":41697.6,"ownership":{"direct":true},"balance_after":186020,"source":{"system":"sec-edgar","filing":"0001415889-24-028567","document":"form4-12072024_121247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028567/form4-12072024_121247.xml","form_type":"4"}},{"id":1340482,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-07T00:15:51.000Z","date":"2024-12-04","kind":"sale","planned":false,"acquired":false,"shares":45000,"price":13.9543,"value":627943.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $13.9543, and the range of prices were between $13.77 and $14.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":136380,"source":{"system":"sec-edgar","filing":"0001415889-24-028567","document":"form4-12072024_121247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028567/form4-12072024_121247.xml","form_type":"4"}},{"id":1340481,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-07T00:15:51.000Z","date":"2024-12-04","kind":"exercise","planned":false,"acquired":true,"shares":45000,"price":0.84,"value":37800.0,"ownership":{"direct":true},"balance_after":181380,"source":{"system":"sec-edgar","filing":"0001415889-24-028567","document":"form4-12072024_121247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028567/form4-12072024_121247.xml","form_type":"4"}},{"id":1342940,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-05T02:45:05.000Z","date":"2024-12-03","kind":"exercise","planned":false,"acquired":false,"shares":41740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"Immediately exercisable."}],"balance_after":194640,"derivative":{"exercise_price":0.84,"expiration_date":"2029-07-04","underlying":"Common Stock","underlying_shares":41740},"source":{"system":"sec-edgar","filing":"0001415889-24-028351","document":"form4-12042024_091201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028351/form4-12042024_091201.xml","form_type":"4"}},{"id":1342939,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-05T02:45:05.000Z","date":"2024-12-03","kind":"exercise","planned":false,"acquired":false,"shares":3260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.84,"expiration_date":"2029-12-16","underlying":"Common Stock","underlying_shares":3260},"source":{"system":"sec-edgar","filing":"0001415889-24-028351","document":"form4-12042024_091201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028351/form4-12042024_091201.xml","form_type":"4"}},{"id":1342938,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-05T02:45:05.000Z","date":"2024-12-02","kind":"exercise","planned":false,"acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":3260,"derivative":{"exercise_price":0.84,"expiration_date":"2029-12-16","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001415889-24-028351","document":"form4-12042024_091201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028351/form4-12042024_091201.xml","form_type":"4"}},{"id":1342937,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-05T02:45:05.000Z","date":"2024-12-03","kind":"sale","planned":false,"acquired":false,"shares":45000,"price":13.1867,"value":593401.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $13.1867, and the range of prices were between $13.00 and $13.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":136380,"source":{"system":"sec-edgar","filing":"0001415889-24-028351","document":"form4-12042024_091201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028351/form4-12042024_091201.xml","form_type":"4"}},{"id":1342936,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-05T02:45:05.000Z","date":"2024-12-03","kind":"exercise","planned":false,"acquired":true,"shares":41740,"price":0.84,"value":35061.6,"ownership":{"direct":true},"balance_after":181380,"source":{"system":"sec-edgar","filing":"0001415889-24-028351","document":"form4-12042024_091201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028351/form4-12042024_091201.xml","form_type":"4"}},{"id":1342935,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-05T02:45:05.000Z","date":"2024-12-03","kind":"exercise","planned":false,"acquired":true,"shares":3260,"price":0.84,"value":2738.4,"ownership":{"direct":true},"balance_after":139640,"source":{"system":"sec-edgar","filing":"0001415889-24-028351","document":"form4-12042024_091201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028351/form4-12042024_091201.xml","form_type":"4"}},{"id":1342934,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-05T02:45:05.000Z","date":"2024-12-02","kind":"sale","planned":false,"acquired":false,"shares":45000,"price":13.6715,"value":615217.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $13.6715, and the range of prices were between $13.324 and $14.035. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":136380,"source":{"system":"sec-edgar","filing":"0001415889-24-028351","document":"form4-12042024_091201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028351/form4-12042024_091201.xml","form_type":"4"}},{"id":1342933,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-12-05T02:45:05.000Z","date":"2024-12-02","kind":"exercise","planned":false,"acquired":true,"shares":45000,"price":0.84,"value":37800.0,"ownership":{"direct":true},"balance_after":181380,"source":{"system":"sec-edgar","filing":"0001415889-24-028351","document":"form4-12042024_091201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028351/form4-12042024_091201.xml","form_type":"4"}},{"id":1349395,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-11-27T21:11:54.000Z","date":"2024-11-27","kind":"sale","planned":false,"acquired":false,"shares":25000,"price":14.39,"value":359750.0,"ownership":{"direct":true},"balance_after":136380,"source":{"system":"sec-edgar","filing":"0001415889-24-027843","document":"form4-11272024_091151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924027843/form4-11272024_091151.xml","form_type":"4"}},{"id":1349394,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-11-27T21:11:54.000Z","date":"2024-11-26","kind":"sale","planned":false,"acquired":false,"shares":42186,"price":14.0466,"value":592569.8676,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $14.0466, and the range of prices were between $13.95 and $14.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":161380,"source":{"system":"sec-edgar","filing":"0001415889-24-027843","document":"form4-11272024_091151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924027843/form4-11272024_091151.xml","form_type":"4"}},{"id":1349393,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-11-27T21:11:54.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":32814,"price":14.0008,"value":459422.2512,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $14.0008, and the range of prices were between $14.00 and $14.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":203566,"source":{"system":"sec-edgar","filing":"0001415889-24-027843","document":"form4-11272024_091151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924027843/form4-11272024_091151.xml","form_type":"4"}},{"id":1687838,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-01-04T21:41:27.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years."}],"balance_after":350000,"derivative":{"exercise_price":5.58,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001209191-24-000806","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919124000806/doc4.xml","form_type":"4"}},{"id":2062719,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2023-01-05T22:00:46.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years."}],"balance_after":165000,"derivative":{"exercise_price":8.42,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001209191-23-001929","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919123001929/doc4.xml","form_type":"4"}},{"id":2120067,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2022-11-10T23:00:54.000Z","date":"2022-11-08","kind":"grant","acquired":true,"shares":82733,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for a stock option to acquire 70,000 shares of common stock of ARS with the exercise price of $1.70 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":82733,"derivative":{"exercise_price":1.44,"expiration_date":"2031-12-14","underlying":"Common Stock","underlying_shares":82733},"source":{"system":"sec-edgar","filing":"0001209191-22-056447","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122056447/doc4.xml","form_type":"4"}},{"id":2120066,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2022-11-10T23:00:54.000Z","date":"2022-11-08","kind":"grant","acquired":true,"shares":48260,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for a stock option to acquire 40,833 shares of common stock of ARS with the exercise price of $0.99 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":48260,"derivative":{"exercise_price":0.84,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":48260},"source":{"system":"sec-edgar","filing":"0001209191-22-056447","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122056447/doc4.xml","form_type":"4"}},{"id":2120065,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2022-11-10T23:00:54.000Z","date":"2022-11-08","kind":"grant","acquired":true,"shares":236380,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS under the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock."}],"balance_after":236380,"derivative":{"exercise_price":0.84,"exercise_date":"2022-11-08","expiration_date":"2029-07-05","underlying":"Common Stock","underlying_shares":236380},"source":{"system":"sec-edgar","filing":"0001209191-22-056447","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122056447/doc4.xml","form_type":"4"}},{"id":2120064,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2022-11-10T23:00:54.000Z","date":"2022-11-08","kind":"grant","acquired":true,"shares":236380,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS under the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":236380,"derivative":{"exercise_price":0.84,"expiration_date":"2029-07-05","underlying":"Common Stock","underlying_shares":236380},"source":{"system":"sec-edgar","filing":"0001209191-22-056447","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122056447/doc4.xml","form_type":"4"}},{"id":2120063,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-11-10T23:00:54.000Z","date":"2022-11-08","kind":"grant","acquired":true,"shares":236380,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 200,000 shares of common stock of ARS Pharmaceuticals, Inc. (\"ARS\") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), as amended (the \"Merger Agreement\"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the \"Merger\"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer.  Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock.  Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc."}],"balance_after":236380,"source":{"system":"sec-edgar","filing":"0001209191-22-056447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122056447/doc4.xml","form_type":"4"}}]}